Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of lenalidomide and dexamethasone for chronic lymphocytic leukaemia that has got worse or come back after treatment (LenD)
This trial looked at low dose lenalidomide and the steroid dexamethasone for people who had already had treatment for chronic lymphocytic leukaemia (CLL).
More about this trial
- see how well the combination of dexamethasone and low dose lenalidomide works for people in this situation
- learn more about the side effects
Summary of results
- 4 people (33%) stopped treatment early because they had serious side effects
- 4 people (33%) stopped treatment early because their CLL got worse
- got a bit better in 3 people (25%)
- stayed the same in 2 people (17%)
- got worse in 7 people (58%)
How to join a clinical trial
Dr Amit C. Nathwani
NIHR Clinical Research Network: Cancer
University College London (UCL)